But the company still has a lot to prove with ERAS-0015.
ApexOnco Front Page
Recent articles
The company will start three phase 3 trials of its G12D project this year.
The Titan CD8-guiding technology seems to have spawned a new variant.
A single-arm trial was enough for J&J’s Inlexzo nod.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
ESMO and the Triple Meeting approach.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
